India's economic engine is revving up, but navigating the global headwinds requires sharp strategy. The rupee's recent volatility against the dollar underscores the complexities facing Indian businesses, impacting everything from import-export trade to domestic inflation. This week alone, we've seen significant shifts in the IT sector, with major players announcing restructuring and a renewed focus on AI-driven solutions. Meanwhile, the burgeoning startup ecosystem continues to attract substantial funding, despite a cautious global investor sentiment. The government's recent policy announcements on infrastructure development and digitalization are poised to further shape the business landscape, creating both opportunities and challenges for entrepreneurs and established corporations alike. Understanding these market dynamics is crucial for success in today's rapidly evolving Indian economy. Stay informed with Abtak.com for the latest insights and analysis on key sectors including finance, manufacturing, and technology – empowering your business decisions in a dynamic market. Explore the complete business news section now to stay ahead of the curve.
, /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company received marketing authorization in from National Medical (TASE:PMCN) Products Administration (NMPA) for the first domestically developed trophoblast cell-surface antigen 2 (TROP2)-directed antibody"drug conjugate (ADC) sacituzumab tirumotecan (sac-™T, formerly SKB264/MK-2870) for adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting). This is the first domestically developed TROP2 ADC approved for marketing in and the first domestically developed ADC fully approved for marketing in . The approval is based on the positive results from a randomized, controlled, phase 3 OptiTROP-Breast01 study in adult patients with unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting). Sac-™T demonstrated statistically significant and clinically meaningful improvement in both progression-free survival (PFS) and overall survival (OS) compared to chemotherapy. The results were presented at the special clinical science symposium for next-generation ADCs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in . Previously, NMPA has accepted two supplemental new drug applications (sNDA) seeking the approvals of sac-™T monotherapy for the treatment of patients with locally advanced or metastatic EGFR-mutant non-small cell lung cancer (NSCLC) following progression on EGFR-TKI therapy only, or both EGFR-TKI and platinum-based chemotherapy, respectively. Dr. , CEO of Kelun-Biotech said, "It is a great pleasure to share with you the important milestone moment of the successful approval and launch of sacituzumab tirumotecan in , which is a significant achievement of Kelun-Biotech's years of deep-rooted source innovation. As the company's first proprietary TROP2 ADC innovative drug, the successful launch of sacituzumab tirumotecan officially opens up a new pattern for the treatment of patients with 2L+ advanced TNBC. We expect that its excellent clinical efficacy and safety results will significantly enhance the clinical benefits and improve the quality of life of patients with advanced TNBC. In the future, we will continue to explore the clinical value of sacituzumab tirumotecan in other indications, maximize the market potential of sacituzumab tirumotecan, and satisfy the clinical needs of patients nationwide." ABOUT MARKET VALUE Breast cancer is a threat to women's lives and health. Among them, triple-negative breast cancer has unique biological behavioral characteristics, and is also known as the "most toxic" breast cancer. 2022 analysis of malignant tumor epidemiology data shows that there are 357,000 new cases of breast cancer and 75,000 deaths in Chinese women annually . In the absence of effective therapeutic targets for triple-negative breast cancer, chemotherapy is the most important systemic treatment in the clinic but it often has poor efficacy and high toxicity and side effects, and the prognosis is different from other subtypes of breast cancer , it is vital to explore more therapeutic means to improve the clinical benefit. ABOUT sac-TMT Sac-™T, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, breast cancer (BC), gastric cancer (GC), gynecological tumors, among others. Sac-™T is developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor with a drug-to-antibody-ratio (DAR) of 7.4. Sac-™T specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells. Kelun-Biotech（6990.HK）is a holding subsidiary of Kelun Pharmaceutical (TADAWUL:2070) (002422.SZ), which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 1 project has been approved for marketing, 3 projects are in the NDA stage, and more than 10 projects are in the clinical stage. The company has established one of the world's leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage, and multiple ADC or novel ADC projects in clinical or preclinical research stage. For more information, please visit https://kelun-biotech.com/.
New Delhi, Dec 17 (PTI) Biopharmaceutical firm Bristol Myers Squibb (BMS) and IT services company Accenture on Wednesday announced the opening of a new AI-powered content hub, Mosaic, in Mumbai. The generative AI-enabled facility is designed to accelerate BMS's global commercialisation strategy through enhanced digital capabilities, enabling the rapid creation of hyper-personalised, patient-centric content tailored for healthcare professionals, according to a joint statement. The launch of Mosaic is a key component of BMS's ongoing USD 130 million strategic investment aimed at advancing its ...Read More >
MUMBAI: When the toughest battle moves from the boardroom to the personal front, even the sharpest minds know it's time to step back and focus on winning the most important fight of all. Kate Rouch, chief marketing officer at OpenAI, has announced she is stepping down from her role to focus on recovery following a diagnosis of late-stage breast cancer. In a heartfelt LinkedIn post, Rouch revealed she was diagnosed around a year and a half ago, shortly after taking on the CMO position. Despite undergoing intensive treatment, she continued to lead the company's marketing function through what s ...Read More >
Mumbai: Dr Reddy's Laboratories has entered into a collaboration with Reykjavik, Ireland-based biotech company Alvotech to co-develop, manufacture and commercialise a biosimilar version of blockbuster cancer drug Keytruda for the global markets. Keytruda (generic name is pembrolizumab), manufactured and marketed by Merck & Co, is the most successful medicine, recording worldwide sales of $29.5 billion in 2024. It is used to treat multiple forms of cancer. Under the terms of the agreement, both companies will be jointly responsible for developing and manufacturing the biosimilar candidate and ...Read More >
New Delhi: Chief minister Rekha Gupta on Sunday said authorities cannot go against demolition orders issued by courts and stressed that displaced residents have been provided accommodation.Her words came in the wake of the recent Madrasi Camp demolition for which the opposition Aam Aadmi Party (AAP) has criticised her. AAP has targeted Gupta, and alleged that the displaced Madrasi Camp residents were provided homes in faraway Narela, and those lack basic amenities.Attending an event to mark the construction of a Jan Sewa camp at a slum cluster in the Haiderpur area, Gupta told reporters: "In t ...Read More >
A major Chinese clinical study on ovarian cancer has been published in CA: A Cancer Journal for Clinicians, one of the world's highest-impact medical journal, marking a first for a Chinese researcher-led gynecological cancer trial, researchers said in Beijing on Sunday. The phase III FZOCUS-1 study tested fluzoparib, a PARP inhibitor developed by Chinese pharmaceutical giant Hengrui Pharma. The trial evaluated the drug as a "maintenance" therapy, treatment given to prevent cancer recurrence afte ...Read More >
New Delhi [India], July 20 (ANI): The Indian Council of Medical Research (ICMR), through its Regional Medical Research Centre, Bhubaneswar (RMRCBB) and National Institute of Malaria Research (NIMR), in partnership with the Department of Biotechnology-National Institute of Immunology (DBT-NII), is currently developing a novel recombinant chimeric malaria vaccine candidate, named AdFalciVax. AdFalciVax is the first indigenous recombinant chimeric malaria vaccine specifically designed to target two critical stages of Plasmodium falciparum, the parasite responsible for the most lethal form of mal ...Read More >
Nagpur: Eminent neurologists from the city joined experts from across the globe on World Brain Tumour Day to raise awareness about the disease.At an event held at the Indian Medical Association (IMA) headquarters in Nagpur, specialists emphasised the importance of early diagnosis, discussed symptoms and treatment options, and highlighted the multifaceted challenges faced by patients and their families.Renowned neurologist and Padma Shri Dr Chandrashekhar Meshram stressed the need for timely detection and comprehensive care. He said awareness about the type of brain tumour and its symptoms is c ...Read More >
Hyderabad: A brain tumour diagnosis often triggers fear -- not just from the disease but from the invasive treatments that follow. Surgery, radiation, long hospital stays and uncertain outcomes overwhelm patients and families. But this World Brain Tumour Day on Sunday brings new hope, as doctors highlight emerging non-invasive therapies that could transform care. Advances in medical technology are introducing targeted, non-surgical treatments that promise better outcomes with fewer side effects and faster recovery. One such breakthrough is Focused Ultrasound Therapy. "It uses sound energy, l ...Read More >
New Delhi, Jun 27 (PTI) Biocon Ltd on Friday said its arm Biocon Biologics has been granted a notice of compliance by Health Canada for its biosimilar Yesafili injection used to treat various ailments of the eye. "Health Canada has granted a Notice of Compliance (NOC) for Yesafili(aflibercept), a biosimilar to Eylea injection, in vial and prefilled syringe presentations, 2 mg/0.05 mL on June 26, 2025," a regulatory filing by Biocon said. This approval paves the way for the launch of Yesafili in Canada, scheduled for July 4, 2025, it said, adding Yesafili is the first biosimilar to Eylea to b ...Read More >
Childhood cancer is a disease no child should ever have to face. Yet, the reality is sobering: around four lakh children worldwide are diagnosed with cancer every year, and nearly 20% of these cases come from India. Awareness is the first step to changing outcomes. This is the most common and often the hardest question to answer. Unlike adult cancers, there are no proven lifestyle or environmental factors that cause cancer in children. Nearly 90% of childhood cancers are sporadic, meaning they h ...Read More >
Hyderabad: Do you or someone close to you experience frequent headaches, numbness or weakness in limbs, seizures, vision or speech changes, imbalance, or sudden memory issues? These could be early symptoms of a brain tumour, a serious and potentially life-threatening neurological condition. The brain is an important part of our body. If these symptoms become more frequent or severe, it could indicate the growth of a brain tumor. Brain tumors are also a type of health emergency -- they often grow slowly but can strike suddenly. Highlighting the unparallel role brain plays and the damage tumors ...Read More >
Biologic therapies are transforming severe asthma treatment by offering the potential for remission, shifting care from symptom control to targeted, personalized approaches. Treatments like dupilumab and tezepelumab have shown efficacy across diverse patient profiles, including complex asthma cases. However, significant barriers remain, particularly cost and access, limiting their availability, especially in underserved communities. Experts stress the need for equitable healthcare solutions to ensure these transformative treatments reach all patients in need. As biologics continue to revolutio ...Read More >
Biopharmaceutical company Boehringer Ingelheim has launched a next generation poultry vaccine for Marek's disease in the country. The product represents a breakthrough in vaccine engineering and recommended for in-ovo vaccination of 18 to 19-day-old embryonated chicken eggs and one-day old chickens to protect against the virulent Marek's disease, the company said in a release on Tuesday (November 26, 2024). The vaccine offers enhanced protection through an innovative controlled attenuation process, delivering right balance between safety and efficacy. Marek's disease remains a significant ch ...Read More >
New Delhi, Oct 23 (PTI) Under a fifth of women in low and middle-income countries having breast or cervical cancer are diagnosed at an early stage, compared to two in every five in high-income countries, according to a study published in The Lancet journal, highlighting disparities in cancer care around the world. Too many women, especially in low and middle-income countries, are only diagnosed when their cancer is already advanced, reducing their chances of survival compared to women in wealthier nations. The 'VENUSCANCER' study, led by researchers forming the 'Cancer Survival Group' at the ...Read More >
New Delhi, March 31 (SocialNews.XYZ) India's bioeconomy is approaching the $200 billion mark, which is a significant milestone in its evolution with a strong policy push and growing innovation pipeline signalling the next phase of growth, according to a report released on Tuesday. The report by Endiya Partners said that the nation's bioeconomy has expanded sharply from around $10 billion in 2014 to over $195 billion in 2026, now contributing nearly 5 per cent to the GDP. India, long recognised as the 'Pharmacy of the World' for supplying nearly 20 per cent of global generics and over 60 per ...Read More >
Srinagar, Apr 02: The Jammu and Kashmir Government informed the Legislative Assembly that chemotherapy services across hospitals are being delivered strictly in accordance with Tata Memorial Centre (TMC) guidelines, with no violations reported. The details were shared in response to a starred question tabled by MLA R.S. Pathania regarding Cancer Treatment Institutes in the UT operating day-care facilities. The house was informed that the Cancer Institutes/Oncology Departments function as Day Care Centres exclusively for administering chemotherapy for solid tumours. "These services are provid ...Read More >
NewsVoir Ahmedabad (Gujarat) [India], December 12: Ahmedabad University has built an innovative academic ecosystem, redefining the ways of learning through research-driven thinking, hands-on experiences, and interdisciplinary exploration. The University has reimagined the classroom experience to equip students to tackle complex global challenges that lie at the intersection of diverse disciplines - a foundation that not only shapes the future of education but also drives societal progress. The University has rapidly emerged as a high-quality multidisciplinary institution, renowned for its tr ...Read More >
Mumbai, Jul 10 (PTI) More than 14,500 women in Maharashtra's Hingoli have been detected with "cancer-like symptoms" during screening under the Sanjivani scheme, state health minister Prakash Abitkar informed the assembly on Thursday. A total of 2,92,996 were surveyed since March 8 there during which they had to answer a questionnaire related to cancer symptoms, Abitkar said in a written reply in the House. "Out of these, 14,542 women were detected with cancer-like symptoms. So far, three have been diagnosed with cancer of the uterus, one with breast cancer and eight with oral cancer after sc ...Read More >
SCHOTT, a leader in specialty glass, initiates local production of high-precision glass tubing for syringes and cartridges in Gujarat, India. This marks a significant step in India's pharmaceutical sector, aligning with the 'Make in India' initiative, enhancing SCHOTT's role in the Asian market. In a notable development in India's pharmaceutical landscape, SCHOTT has successfully commenced local production of high-precision glass tubing for syringes and cartridges at its Jambusar, Gujarat facili ...Read More >
Mumbai, Oct 31 (SocialNews.XYZ) Actress Deepika Padukone, who has been a strong advocate for mental health awareness, reacted to cricketer Jemimah Rodrigues' recent revelation about battling anxiety. The 'Om Shanti Om' actress, known for openly sharing her own struggles with depression in the past, praised Jemimah for her honesty and courage in speaking up, highlighting the importance of conversations around mental well-being in sports and beyond. Taking to her Instagram Stories, Deepika Padukone reshared a video of cricketer Jemimah Rodrigues, in which the athlete opened up about her struggl ...Read More >
First & only immuno-oncology drug approved by various regulatory authorities around the world Dr. Reddy's Laboratories has announced the launch of Toripalimab in India. Toripalimab is a New Biological Entity (NBE). It is the only immuno-oncology drug approved by various regulatory authorities around the world such as United States Food and Drug Administration (USFDA), European Medicines Agency (EMA), Medicines and Healthcare products Regulatory Agency (MHRA), and others for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). In 2023, Dr. Reddy's entered in ...Read More >
New Delhi, Dec 17 (PTI) Biopharmaceutical firm Bristol Myers Squibb (BMS) and IT services company Accenture on Wednesday announced the opening of a new AI-powered content hub, Mosaic, in Mumbai. The generative AI-enabled facility is designed to accelerate BMS's global commercialisation strategy through enhanced digital capabilities, enabling the rapid creation of hyper-personalised, patient-centric content tailored for healthcare professionals, according to a joint statement. The launch of Mosaic is a key component of BMS's ongoing USD 130 million strategic investment aimed at advancing its ...Read More >
Bengaluru: Global biopharmaceutical company AstraZeneca is investing Rs166 crore to expand its Bengaluru operations, creating 400 new jobs. The upgraded facility will support around 1,300 employees and enhance the company's capabilities in AI-driven R&D, global business services, IT, and digital health, strengthening its presence in India.This investment follows AstraZeneca's recent expansion of its Global Innovation and Technology Centre (GITC) in Chennai. The company's workforce in India will increase to 4,000 employees, highlighting India's growing significance in AstraZeneca's global opera ...Read More >
New Delhi: Enrolment of about 10,500 participants in the phase III clinical trial of the indigenous one-shot Panacea Biotec developed dengue vaccine, DengiAll, is likely to be completed by October across 20 centres in India, according to ICMR scientists. So far, 8,000 participants in various centres at Pune, Chennai, Kolkata, Delhi and Bhubaneswar, among others, have received either the vaccine or a placebo as part of the trial sponsored by the Indian Council of Medical Research (ICMR) and Panacea Biotec. The trial is co-led by ICMR-National Institute of Translational Virology and AIDS resea ...Read More >
Hyderabad, April 6 (RAHNUMA): CuraTeQ Biologics, a subsidiary of Aurobindo Pharma, has announced positive top-line results from its Phase 3 trial of BP11, an investigational biosimilar to Omalizumab (marketed as Xolair). The study met all primary endpoints, demonstrating strong comparability with the reference drug in treating chronic spontaneous urticaria (CSU) at a 300 mg dose. Conducted across 608 patients at nearly 80 sites in Europe and India, the trial showed precise equivalence in itch severity reduction at Week 12, aligning with requirements of both the Food and Drug Administration an ...Read More >
Mumbai: Television star Hina Khan revealed her stage-three breast cancer diagnosis in June 2024. Through social media, she shared her journey, receiving praise for her strength and openness. Fans admired her positivity, but fellow actress Rozlyn Khan has questioned the accuracy of her claims. Hina claimed she underwent a 15-hour surgery and traveled extensively during chemotherapy. Rozlyn Khan said, "In Stage 3, surgery first, chemotherapy and then it comes to radiation. These are the procedures. For the past two years, I have been eagerly learning about cancer and working on creating more an ...Read More >
Coimbatore: There is an alarming rise in breast and cervical cancer cases in the district. If the data available with the 13 govt hospitals that screen for breast and cervical cancers in Coimbatore is anything to go by, the test positivity rate is steadily increasing by 2% to 4% every year. "Nowadays, women, irrespective of their age group, are vulnerable for breast and cervical cancers. Early menstruation, late menopause and obesity are major reasons for breast cancer. Women consuming excessive fatty foods and alcohol could also contract breast cancer. Women with poor vaginal hygiene, multipl ...Read More >
Bengaluru: Brain tumour diagnoses in Bengaluru rose by 30% in the last few years. However, doctors say the numbers don't tell a story of panic, but rather of progress. One key reason, medical experts believe, is growing public awareness about brain tumour symptoms, prompting more people to seek medical attention early.Dr Arjun Srivatsa, director and head of the Institute of Neurosciences at Sakra World Hospital, explained to TOI, "First, there's greater awareness among the general population about the symptoms and signs of brain tumours, which means more people are coming in earlier for evalua ...Read More >
New Delhi [India], July 20 (ANI): The Indian Council of Medical Research (ICMR), through its Regional Medical Research Centre, Bhubaneswar (RMRCBB) and National Institute of Malaria Research (NIMR), in partnership with the Department of Biotechnology-National Institute of Immunology (DBT-NII), is currently developing a novel recombinant chimeric malaria vaccine candidate, named AdFalciVax. AdFalciVax is the first indigenous recombinant chimeric malaria vaccine specifically designed to target two critical stages of Plasmodium falciparum, the parasite responsible for the most lethal form of mal ...Read More >
Bengaluru: Karnataka chief minister Siddaramaiah's comments suggesting Covid-19 vaccination may have caused the recent heart-attack related deaths in the state's Hassan district has triggered a wave of rebuttals from senior doctors, Biocon founder Kiran Mazumdar-Shaw and the BJP. The All India Institute of Medical Sciences dismissed any connection between the two. A study on the people who succumbed to sudden cardiac arrests did not reveal any link to the Covid vaccination, said Karan Madan, associate professor at the Department of Pulmonary, Critical Care and Sleep Medicine at AIIMS-Delhi. T ...Read More >